Ergoteles’s Passage Bio PASG Stock Holding History

Ergoteles’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,890	Closed	-$52.2K	–	1635
2022 Q4	$52.2K	Sell	1,890 -1,913	-50%	-$48.3K	﹤0.01%	1288
2022 Q3	$95K	Sell	3,803 -4,614	-55%	-$182K	﹤0.01%	1394
2022 Q2	$397K	Buy	+8,417	New	+$393K	0.01%	955

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Ergoteles's PASG Position: Q1 2023 in Review

Ergoteles sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 1,890 shares — an estimated $52.2K sold.

Ergoteles first reported a position in PASG in Q2 2022 and held it in 3 quarters. The position peaked at $397K in Q2 2022. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

Ergoteles reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,890 Passage Bio shares in Q1 2023, an estimated $52.2K.
Ergoteles first reported a position in Passage Bio in Q2 2022 and held it in 3 quarters.
Ergoteles's Passage Bio position peaked at $397K in Q2 2022.
58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.